Plain-English translation of NCT04553770 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new cancer drug called to see if it can help shrink early-stage breast cancer before surgery. The study compares two approaches: taking the medication alone, or taking it together with a hormone therapy pill. The goal is to find out which combination works best at helping the cancer disappear completely before patients have surgery.
Most breast cancer treatments are designed for cancers with high levels of a protein called HER2, but some cancers have low levels of this protein and don't respond well to standard treatments. This trial is exploring whether this new medication can help people whose cancers have low HER2 levels, potentially giving them a better treatment option.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the new medication alone or the new medication combined with a hormone pill. You will receive the medication through an IV infusion every 3 weeks for up to 6 cycles (about 4 to 5 months total), then have surgery. During treatment, you'll have regular check-ups to monitor how well the treatment is working and watch for any side effects, and you'll complete a short questionnaire about how you're feeling.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States